In conclusion, this study demonstrates a substantial proportion of HSCT patients receiving HBV vaccination will fail to respond to the first vaccination series, and that subsequent vaccination series can improve the rates of seroconversion. These results highlight the need to assess serologic response in HSCT patients following HBV vaccination and the utility of continuing vaccination until protective immunity is achieved, a recommendation not emphasised in current post-transplant vaccination guidelines. [Extracted from the article]